Visudyne.com
  Novartis Pharma US

 
THE WORLD IS BEAUTIFUL > TO LOOK AT

References

  1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on outcomes—TAP report no. 3. Arch Ophthalmol. 2002;120:1443-1454.


  2. Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract. 2002;15:144-145.


  3. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1992;99:933-943.


  4. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984; 102:1640-1642.


  5. AMD Alliance International. AMD Information. Available at: http://amdalliance.com


  6. Bressler SB, Bressler NM, Fine SL, et al. Age-related macular degeneration. Surv Ophthalmol. 1988;32:385-392.


  7. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1220-1231.


  8. Colenbrander A, Fletcher DC. Basic concepts and terms for low vision rehabilitation. Am J Occup Ther. 1995;49:865-869.


  9. West SK, Rubin GS, Broman AT, et al, for the SEE Project. How does visual impairment affect performance on tasks of everyday life? The SEE Project. Arch Ophthalmol. 2002;120:774-780.


  10. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol. 1997;115:741-747.


  11. Bressler SB, Bressler NM, Fine SL, et al. Natural course of choroidal neovascular membranes within the foveal avascular zone in senile macular degeneration. Am J Ophthalmol. 1982;93:157-163.


  12. Pizzarello LD. The dimensions of the problem of eye disease among the elderly. Ophthalmology. 1987;94:1191-1195.


  13. Klein R, Klein BEK, Tomany SC, et al. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2002;109:1767-1779.


  14. Thylefors B, Négrel A-D, Pararajasegaram R, Dadzie KY. Global data on blindness. Bull WHO. 1995;73:115-121.


  15. Hyman LG, Lillienfeld AM, Ferris FL III, et al. Senile macular degeneration: a case-control study. Am J Epidemiol. 1983;118:213-227.


  16. DeAngelis MM, Lane AM, Shah CP, et al. Extremely discordant sib-pair study design to determine risk factors for neovascular age-related macular degeneration. Arch Ophthalmol. 2004;122:575-580.


  17. Ciulla TA, Danis RP, Harris A. Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol. 1998;43:134-146.


  18. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Arch Ophthalmol. 1994;112:489-499.


  19. Aveline B, Hasan T, Redmond RW, et al. Photophysical and photosensitizing properties of benzoporphyrin derivative monoacid ring A (BPD-MA). Photochem Photobiol. 1994;59:328-335.


  20. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45:195-214.


  21. Rubin GS, Bandeen-Roche K, Huang G-H, et al. The association of multiple visual impairments with self-reported visual disability: SEE Project. Invest Ophthalmol Vis Sci. 2001;42:64-72.


  22. Ross JE, Bron AJ, Clarke DD. Contrast sensitivity and visual disability in chronic simple glaucoma. Br J Ophthalmol. 1984;68:821-827.


  23. Schmidt-Erfurth U, Elsner H, Terai N, et al. Effects of verteporfin therapy on central visual field function. Ophthalmology. 2004;111:931-939.


  24. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc. 1998;46:58-64.


  25. Williams RA, Brody BL, Thomas RG, et al. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998;116:514-520.


  26. Fletcher DC, Schuchard RA. Preferred retinal loci relationship to macular scotomas in a low-vision population. Ophthalmology. 1994;104:632-638.


Home  |  Professional Main Page  |  About AMD
About Visudyne  |  Ordering Visudyne
Patient InSight Registry  |  Resources
Prescribing Information  |  Important Safety Information
Links  |  eSlide Library

Contact Us  |  Site Guide  |  Site Map
Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement .
Copyright ©2008
Novartis Pharmaceuticals Corporation. All rights reserved.

Novartis proudly supports the Together Rx Access program.
Together Rx Access